Thalidomide, an immunomodulatory drug, is a potent vascular endothelial growth factor (VEGF) inhibitor, and it is frequently used to treat multiple myeloma in adults (Franks et al., 2004; Kenyon et al., 1997; D'Amato et al., 1994). The gene discussed is VEGFA; the disease is plasma cell myeloma.